Introduction
The potential importance ofchemoprevention in populations at increased risk for colorectal cancer has been emphasized in recent years. This is partly because improvements in chemotherapy, radiotherapy, and surgery have not significantly changed the prognosis ofcolorectal cancer, and this malignancy is still one of the leading causes of morbidity and mortality in western countries (1) . Epidemiologic studies and studies in rodent models have indicated a possible chemopreventive role for various natural substances and pharmacologic agents (2, 3) . However, their effect on prevention of human disease has generally not been clearly established, and large clinical trials in humans are need for definitive results.
One of the main problems in planning large, chemopreventive interventions in humans is that the development of malignant neoplasms is a slow, multistep process that usually takes many years. Moreover, the incidence ofcancer in the general population is relatively low. Therefore, carrying out human chemopreventive intervention studies that decrease morbidity and mortality with neoplasia as an end point has been very time comsuming and costly. Insufficient subjects or short follow-up periods significantly decrease the power of these studies, making it impossible to detect real but small protective effects of chemopreventive agents.
Therefore, it appears to be essential to develop and validate intermediate biomarkers ofabnormal cell growth and maturation for use in chemopreventive intervention studies. These biomarkers should be the result ofactual events occurring the initiation and promotional phases of tumor development in order to be optimum candidates for modification by chemopreventive agents. Intermediate biomarkers with these characteristics can also be tested for their role in identifying populations at increased risk for cancer and in developing human screening programs with reasonable cost-benefit ratios (4).
Biomarkers of Increased Susceptibility to Gastrointestinal Cancer
Intermediate biomarkers of abnormal cell growth in human subjects have been developed through several investigative approaches. These include the identification of individuals or population groups at either increased or at low risk for neoplasia and the application of these groups to studies identifying biomarkers that can be modulated by nutritional and chemopreventive interventions.
Ideal 
Biomarkers of Cell Proliferation
The incorporation of labeled DNA precursors by cells in S phase of the proliferative cycle is an effective and reliable way to measure cell proliferation in renewing tissue (4).
[3H]Deoxythymidine (dThd) has been used fairly extensively in studies of cell proliferation in human and rodent tissues, and it has been possible to define normal numbers of cells and spatial patterns of proliferating and differentiating cells in renewing mammalian tissues and alterations in the cells and tissues of patients at increased risk for neoplasia. With these measurements, patterns of cell proliferation have been shown to be modified in several groups of human subjects previously identified as being at increased risk for gastrointestinal cancer Several diseases that affect individuals at increased risk for colorectal cancer have been identified in which the size of the proliferative compartment has increased compared to low-risk subjects (Table 1) . Familial polyposis is an inherited, autosomal dominant disease characterized by a colon lined with adenomatous polyps and the development ofcolorectal cancer at a very early age; several extracolonic manifestations can also be variably present in affected members of the kindreds. The normal-appearing rectal mucosa of the affected patients shows a pattern ofcell proliferation that clearly differs from that ofnormal people. The proliferative compartment of normal colorectal mucosa of individuals at low risk for colorectal cancer, and of normal rodents, is located in the lower part of the colonic crypts. The total labeling index (i.e., labeled cells versus total cells) oflow-risk controls and familial polyposis patients does not differ significantly, but the patients show a shift of the proliferative compartment toward the top of the crypts. Thus, the main proliferative alteration noted in the colonic mucosa ofthese patients is not an increase in overall cell proliferation labeling index, but a lumenward displacement ofthe zone ofactive cell proliferation in the crypts [see, for example, Deschner et al. (6,7) and Lipkin et al. (8, 9) ].
The polyp or dysplasia cancer sequence is a generally accepted hypothesis related to the pathogenesis of colon cancer (20, 21) , and patterns of cell proliferation in patients with adenomatous polyps have been widely studied. It has been reported that an expansion ofthe proliferative compartment is present along the entire colon in individuals at increased risk, no matter where the lesion is (10, 13, 14) . A correlation between size and degree of dysplasia in adenomas and degree ofalteration ofcell proliferation also has been noted (12) . The total labeling index ofpatients with polyps or cancer has been reported to be significantly higher than that of normal controls using [3H]dThd or BrdU in some studies (8, 11) , and in others cell proliferation in the upper crypt significantly increased, with corresponding expansion in size of the proliferative compartment (12, 13, 16) .
Patients with previous surgery for colorectal cancer are known to be at increased risk for a second malignancy; the mucosa of remaining colon has shown increased overall cell proliferation and an increased proliferative compartment size in patients with recurrent polyps compared to nonrecurrent (15) , suggesting an association between increased cell proliferation and risk of methachronous lesions. Chronic ulcerative colitis is a disease characterized by a defined risk of colorectal cancer that is further correlated to the extent and duration ofthe disease. A shift of the proliferative compartment towards the top of the crypt has been found in the normal-appearing mucosa ofpatients with chronic ulcerative colitis (17) (18) (19) .
Several other methods have been used to measure cell proliferation. Ki67 (22) and proliferating cell nuclear antigen (PCNA) (23) arise for measurement ofthe percentage ofcells in S phase determined by cytofluorimetry (25) ; this analysis also can only give an idea about the total labeling index without any distinction of cell proliferation in different parts of the crypt.
Biomarkers of Cell Differentiation
The studies listed in Table 2 are only a selected list with a few illustrations of the topic ofcell differentiation biomarkers. Cell proliferation measurements are now gaining increased complexity (with new groups of PCNA molecules associated with cell cycle functions), and cell differentiation biomarkers are similarly becoming more complex. Multiple measurements are now available to distinguish cycling cells from quiescent proliferative (26) . However, a lack of O-acetyl substituted sialic acid does not seem to be a marker of familial adenomatous polyposis, a condition also associated with increased cancer risk (27) .
Among cell components that develop during their normal and abnormal differentiation, cytokeratins and other intermediate filaments become modified; it has been shown that their compositions and distributions vary in different cell types during different stages ofcell differentiation and in disease states. Thus, the distribution of the brush-border-specific microvillar protein villin, in human colonic mucosa detected by immunohistochemistry, shows an altered pattern in dysplastic and neoplastic disease (28) . Further, different proteins that bind basement membrane glycoprotein laminin have been found in preneoplastic compared to normal mucosa (29) .
Carbohydrate blood group-related antigens are also expressed in colonic epithelial cells and show two kinds of alterations in preneoplastic and neoplastic tissues (31) . The first type involves the synthesis ofnew epitopes not expressed by normal mucosa, usually accomplished by a process of oligosaccharide elongation. An example ofthis is the expression ofthe trifucosyl or extended LeY antigen in adenomas and cancer cells but not in normal mucosa (30) . The second kind ofalteration observed is the unmasking and subsequent expression of normally cryptic antigens following incomplete glycosylation (32) . These antigens are not expressed by normal colonocytes, but they are expressed in premalignant colonic tissue such as dysplastic adenomatous polyps and chronic ulcerative colitis with dysplasia.
Lectin-binding of cell surface carbohydrate residues becomes modified with the differentiation of normal epithelial cells and in stages of development of precancerous diseases. Abnormal patterns of lectin binding have been described in the colorectal mucosa of patients with inflammatory diseases or adenomas (33, 34) .
Further Aspects of the Molecular Biology of Colon Cancer
Oncogene mutations, the overexpression, deletion, and mutation of tumor-suppressor genes, DNA hypomethylation, and other genetic alterations have now been identified in preneoplastic and neoplastic lesions in the colon. The familial adenomatous polyposis gene has been located on chromosome 5, and a recently mapped point mutation and loss of p53 on chromosome 17p has been found in some lesions. DCCand MCC genes have been described, and myc also may be involved (35, 36) . Among many reviews of this topic, several points are relevant for chemoprevention studies.
Having available genetic probes for the disease would naturally help define populations at risk, and detect individuals who could Table 3 . Fiber, calcium, vitamins, and w-3 fatty acids are all constituents of human diets, and various epidemiologic and experimental findings support protective roles for these constutuents against colorectal cancer (3, 4) . Results obtained with fiber have differed depending on types and amounts given in various studies (46) . Calcium has shown more consistent and reproducible results in most animal and human studies, and calcium supplementation in the diet in most studies has reduced expansions ofthe proliferative compartment in patients with familial colon cancer predisposition and sporadic adenomas (37) (38) (39) . Calcium is unable to further decrease an already low level ofproliferation (37) . In one study calcium also was shown to change soybean agglutinin lectin binding, increasing it toward a pattern more typical of well-differentiated cells (40) . Results 
